Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 13, 2009, Pages 3398-3404

  Shen, Hong C ^a   Ding, Fa Xiang ^a   Wang, Siyi ^a   Xu, Suoyu ^a   Chen, Hsuan shen ^a   Tong, Xinchun ^a   Tong, Vincent ^a   Mitra, Kaushik ^a   Kumar, Sanjeev ^a   Zhang, Xiaoping ^a   Chen, Yuli ^a   Zhou, Gaochao ^a   Pai, Lee Yuh ^a   Alonso Galicia, Magdalena ^a   Chen, Xiaoli ^a   Zhang, Bei ^a   Tata, James R ^a   Berger, Joel P ^a   Colletti, Steven L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

sEH; Soluble epoxide hydrolase; Spirocyclic secondary amines; Spontaneously hypertensive rats; Tertiary ureas

Indexed keywords

AMINE; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; LABRASOL; PHENYLCYCLOPROPYLAMINE; PIPERIDINE DERIVATIVE; SPIRO COMPOUND; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; NONHUMAN; RACEMIC MIXTURE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SUBSTITUTION REACTION;

AMINES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL LINE; DRUG DISCOVERY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; RATS; RATS, INBRED SHR; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

RATTUS;

EID: 66349134398     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.036     Document Type: Article

References (39)

1. For a leading review:. Newman J.W., Morisseau C., and Hammock B.D. Prog. Lipid Res. 44 (2005) 1
2. Pacifici G.M., Temellini A., Giuliani L., Rane A., Thomas H., and Oesch F. Arch. Toxicol. 62 (1988) 254
3. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Circ. Res. 87 (2000) 992
4. For a leading review:. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Prog. Lipid Res. 43 (2004) 55
5. For a leading review:. Larsen B.T., Gutterman D.D., and Hatoum O.A. Eur. J. Clin. Invest. 36 (2006) 293
6. Lin W.K., Falck J.R., and Wong P.Y. Biochem. Biophys Res. Commun. 167 (1990) 977
7. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., and Busse R. Nature 401 (1999) 493
8. Spiecker M., and Liao J.K. Arch. Biochem. Biophys. 433 (2005) 413
9. Gross G.J., Hsu A., Flack J.R., and Nithipatikom K. J. Mol. Cell Card. 42 (2007) 687
10. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.-H., Watanabe T., and Hammock B.D. Hypertension 46 (2005) 975
11. Jung O., Brandes R.P., Kim I.-H., Schmidt R., Hammock B.D., Busse R., and Fleming I. Hypertension 45 (2005) 759
12. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Hypertension 39 (2002) 690
13. Zhao X., Yamamoto T., Newman J.W., Kim I.-H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., and Imig J.D. J. Am. Soc. Nephrol. 15 (2004) 1244
14. http://www.aretetherapeutics.com.
15. Gomez G.A., Morisseau C., Hammock B.D., and Christianson D.W. Protein Sci. 15 (2006) 58
16. Delombaert, S.; Eldrup, A. B.; Kowalski, J. A.; Mugge, I. A.; Soleymanzadeh, F.; Swinamer, A. D.; Taylor, S. J. WO2007106705 A1, 2007
17. Ingraham, R. H. WO2007106706 A1, 2007
18. Hammock, B. D.; Jones, P. D.; Morisseau, C.; Huang, H.; Tsai, H.-J.; Gless, R. WO2007106525 A1, 2007
19. Hammock, B. D.; Kim, I.-H.; Morisseau, C.; Watanabe, T.; Newman, J. W. WO2006045119 A2, 2006
20. Eldrup, A. B.; Farrow, N. A.; Kowalski. J. A.; Delombaert, S.; Mugge, I. A.; Soleymanzadeh, F.; Swinamer, A. D.; Taylor, S. J. WO2007098352 A2, 2007
21. Takahashi, H.; Ota, T.; Kakinuma, H. WO2007043652 A1, 2007
22. Ota, T.; Kakahashi, H.; Kakinuma, H.; Busujima, T. WO2007043653 A1, 2007
23. Ingraham, R. H.; Proudfoot, J. R. WO2003002555 A1, 2003
24. Cardozo, M. G.; Ingraham, R. H. WO2006121684 A2, 2006
25. Cywin, C. L.; De Lombaert, S.; Eldrup, A. B.; Ingraham, R. H.; Taylor, S.; Soleymanzadeh, F. WO2006121719 A2, 2006
26. Kroetz, D.; Zeldin, D. C.; Hammock, B. D.; Morisseau, C. US20030119900 A1, 2003
27. Kroetz, D.; Zeldin, D. C.; Hammock, B. D.; Morisseau, C. US20040092487 A1, 2004
28. Hammock, B. D.; Kim, I.-H.; Morisseau, C.; Watanabe, T.; Newman, J. W. US20050026844 A1, 2005
29. Erickson, D.; Hoffman, A. F.; Warren, T. C. WO200023060, 2000
30. Hwang S.H., Tsai H.-J., Liu J.-Y., Morisseau C., and Hammock B.D. J. Med. Chem. 50 (2007) 3825
31. Kim I.-H., Morrisseau C., Watanabe T., and Hammock B.D. J. Med. Chem. 47 (2004) 2110
32. Kim I.-H., Heirtzler F.R., Morisseau C., Hishi K., Tsai H.-J., and Hammock B.D. J. Med. Chem. 48 (2005) 3621
33. Morisseau C., Newman J.W., Tsai H.-J., Baecker P.A., and Hammock B.D. Bioorg. Med. Chem. Lett. 16 (2006) 5439
34. Li H.-Y., Jin Y., Morisseau C., Hammock B.D., and Long Y.-Q. Bioorg. Med. Chem. Lett. 14 (2006) 6586
35. Morisseau C., Newman J.W., Dowdy D.L., Goodrow M.H., and Hammock B.D. Chem. Res. Toxicol. 14 (2001) 409
36. Jamieson C., Moir E.M., Rankovic Z., and Wishart G. J. Med. Chem. 49 (2006) 5029 and references therein
37. Fisslthaler B., Hinsch N., Chataigneau T., Popp R., Kiss L., Busse R., and Fleming I. Hypertension 36 (2000) 270
38. Viswanathan P.C., and Balser J.R. Trends Cardiovasc. Med. 14 (2004) 28
39. +]: 364.63.